QQ客服 官方微博 反馈留言

	XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of I kappa B
	Ming, Mei; Wu, Wenjun; Xie, Bingqing; Sukhanova, Madina; Wang, Weige; Kadri, Sabah; Sharma, Shruti; Lee, Jimmy; Shacham, Sharon; Landesman, Yosef
刊名	MOLECULAR CANCER THERAPEUTICS
	2018
卷号	17期号:12
ISSN号	1535-7163
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3604608
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Ming, Mei,Wu, Wenjun,Xie, Bingqing,et al. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of I kappa B[J]. MOLECULAR CANCER THERAPEUTICS,2018,17(12).
APA	Ming, Mei.,Wu, Wenjun.,Xie, Bingqing.,Sukhanova, Madina.,Wang, Weige.,...&Wang, Y. Lynn.(2018).XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of I kappa B.MOLECULAR CANCER THERAPEUTICS,17(12).
MLA	Ming, Mei,et al."XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of I kappa B".MOLECULAR CANCER THERAPEUTICS 17.12(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。